The Female Health Company to Present at Sidoti & Company Investor Conference on January 12, 2015
CHICAGO, Jan. 6, 2015 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom®, today announced that it will be presenting at the Sidoti & Company Emerging Growth Institutional Investor Forum on Monday, January 12, 2015. The conference will be held at the Grand Hyatt New York Hotel in midtown Manhattan.
The presentation by Karen King, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 9:20 a.m. Eastern Standard Time in Estate 4. Management will also be available during the day for one-on-one meetings. Investors interested in arranging one-on-one meetings should contact their Sidoti representative.
About Sidoti & Company, LLC
Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research, while rapidly becoming a driving force in micro-cap research, launching coverage of more than 500 small-cap and over 200 micro-cap companies since mid-2010. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable small-cap companies, and it continues to expand its coverage of micro-cap equities. Sidoti's research is exclusively available to institutional investors, and its semi-annual conferences are unmatched on Wall Street. Sidoti & Company is also a broker-dealer registered with the SEC and a FINRA member firm.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].
Logo - http://photos.prnewswire.com/prnh/20120712/MM39764LOGO
SOURCE The Female Health Company
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article